Maternal serum placental growth factor and α -fetoprotein testing in first trimester screening for Down syndrome

2013 ◽  
Vol 33 (5) ◽  
pp. 457-461 ◽  
Author(s):  
Kim Donalson ◽  
Steve Turner ◽  
Lesley Morrison ◽  
Päivi Liitti ◽  
Christel Nilsson ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Growth Factor ◽  
First Trimester ◽  
Maternal Serum ◽  
Placental Growth Factor ◽  
First Trimester Screening ◽  
Trimester Screening

scholarly journals Effect of Low-Dose Aspirin on Soluble FMS-Like Tyrosine Kinase 1/Placental Growth Factor (sFlt-1/PlGF Ratio) in Pregnancies at High Risk for the Development of Preeclampsia

2019 ◽  
Vol 8 (9) ◽  
pp. 1429 ◽  
Author(s):  
Karoline Mayer-Pickel ◽  
Vassiliki Kolovetsiou-Kreiner ◽  
Christina Stern ◽  
Julia Münzker ◽  
Katharina Eberhard ◽  
...  
Keyword(s):  
Growth Factor ◽  
High Risk ◽  
Tyrosine Kinase ◽  
Serum Levels ◽  
First Trimester ◽  
Placental Growth Factor ◽  
Chronic Hypertension ◽  
First Trimester Screening ◽  
Trimester Screening ◽  
Plgf Ratio

Background: Soluble FMS-like Tyrosine Kinase 1 (sFlt-1) and placental growth factor (PlGF) have been reported to be highly predictive several weeks before the onset of preeclampsia. Objective: To investigate longitudinal changes of serum levels sFlt-1 and PlGF in pregnant women at high risk for the development of preeclampsia and to reveal an impact of aspirin on maternal serum concentrations of sFlt-1 and PlGF. Methods: This was a prospective longitudinal study in 394 women with various risk factors for the development of preeclampsia (chronic hypertension, antiphospholipid syndrome/APS or systemic lupus erythematosus/SLE, thrombophilia, women with a history of preeclampsia, pathologic first trimester screening for preeclampsia) and 68 healthy women. Serum levels of sFlt-1 and PlGF were measured prospectively at 4-week intervals (from gestational weeks 12 until postpartum). Results: The sFlt-1/PlGF ratio was significantly higher in women with an adverse obstetric outcome compared to women with a normal pregnancy, starting between 20 and 24 weeks of gestation. There was no effect of aspirin on sFlt-1/PlGF ratio in women with chronic hypertension, APS/SLE, thrombophilia and controls. The use of aspirin showed a trend towards an improvement of the sFlt-1/PlGF ratio in women with preeclampsia in a previous pregnancy and a significant effect on the sFlt-1/PlGF ratio in women with a pathologic first trimester screening for preeclampsia. Conclusions: Our findings reveal an impact of aspirin on sFlt-1/PlGF ratio in women with a pathologic first trimester screening for preeclampsia, strongly supporting its prophylactic use.

scholarly journals Predictive Performance of a Seven-Plex Antibody Array in Prenatal Screening for Down Syndrome

2015 ◽  
Vol 2015 ◽  
pp. 1-7
Author(s):  
Jeroen L. A. Pennings ◽  
Sandra Imholz ◽  
Ilse Zutt ◽  
Maria P. H. Koster ◽  
Jacqueline E. Siljee ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Growth Factor ◽  
Prenatal Screening ◽  
Serum Proteins ◽  
Predictive Performance ◽  
First Trimester ◽  
Antibody Array ◽  
First Trimester Screening ◽  
Trimester Screening ◽  
Antibody Arrays

We evaluated the use of multiplex antibody array methodology for simultaneous measurement of serum protein markers for first trimester screening of Down Syndrome (DS) and other pregnancy outcomes such as preeclampsia. For this purpose, we constructed an antibody array for indirect (“sandwich”) measurement of seven serum proteins: pregnancy-associated plasma protein-A (PAPP-A), free beta subunit of human chorionic gonadotropin (fβ-hCG), alpha-fetoprotein (AFP), angiopoietin-like 3 (ANGPTL3), epidermal growth factor (EGF), insulin-like growth factor 2 (IGFII), and superoxide dismutase 1 (SOD1). This array was tested using 170 DS cases and 510 matched controls drawn during the 8th–13th weeks of pregnancy. Data were used for prediction modelling and compared to previously obtained AutoDELFIA immunoassay data for PAPP-A and fβ-hCG. PAPP-A and fβ-hCG serum concentrations obtained using antibody arrays were highly correlated with AutoDELFIA data. Moreover, DS prediction modeling using (log-MoMmed) antibody array and AutoDELFIA data gave comparable results. Of the other markers, AFP and IGFII showed significant changes in concentration, although adding these markers to a prediction model based on prior risk, PAPP-A and fβ-hCG did not improve the predictive performance. We conclude that implementation of antibody arrays in a prenatal screening setting is feasible but will require additional first trimester screening markers.

First Trimester Screening for Fetal Aneuploidies Using Placental Growth Factor: The Great Obstetrical Syndrome (GOS) Study

2018 ◽  
Vol 40 (8) ◽  
pp. 1044-1049 ◽  
Author(s):  
Amélie Boutin ◽  
Suzanne Demers ◽  
Cédric Gasse ◽  
Yves Giguère ◽  
Amélie Tétu ◽  
...  
Keyword(s):  
Growth Factor ◽  
First Trimester ◽  
Placental Growth Factor ◽  
First Trimester Screening ◽  
Trimester Screening ◽  
Fetal Aneuploidies

scholarly journals Fetal Down syndrome screening models for developing countries; Part I: Performance of Maternal Serum Screening

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Chanane Wanapirak ◽  
Wirawit Piyamongkol ◽  
Supatra Sirichotiyakul ◽  
Fuanglada Tongprasert ◽  
Kasemsri Srisupundit ◽  
...  
Keyword(s):  
Developing Countries ◽  
Down Syndrome ◽  
Reference Range ◽  
First Trimester ◽  
Maternal Serum ◽  
Second Trimester ◽  
First Trimester Screening ◽  
Maternal Serum Screening ◽  
Serum Screening ◽  
Trimester Screening

Abstract Background To identify the performance of fetal Down syndrome (DS) screening for developing countries. Methods A prospective study on MSS (maternal serum screening) with complete follow-ups (n = 41,924) was conducted in 32 network hospitals in the northern part of Thailand. Various models of MSS were tested for performance. Results MSS based on Caucasian reference range resulted in very high false positive rate (FPR; 13%) in our country, compared to the rate of 7.8% with our own (Thai) reference range, whereas the detection rate was comparable. As individual screening, C-S (contingent first trimester screening including PAPP-A, and free beta-hCG, classified as a) high risk [> 1:30], indicated for invasive diagnosis; b) intermediate risk [1:30–1500], indicated for STS; and c) low risk [< 1:1500], need no further tests.) was the most effective model (sensitivity 84.9%, FPR 7.7%) but nearly one-third needed the second trimester test (STS) because of intermediate results. Additionally, about one-third had their first visits in the second trimester and had no chance of FTS (first trimester screening). C-S plus STS had a sensitivity of 82.4% and FPR 8.1% whereas independent first and second trimester screening model (I-S) gave the sensitivity of 78.4% and FPR of 7.5% but was much more convenient and practical. Conclusion C-S plus STS was the most effective models while I-S model was also effective and may be better for developing countries because of its simplicity and feasibility.

Sign in / Sign up

Export Citation Format

Share Document